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Background: Complex biological networks of atherosclerosis are largely unknown.
Objective: The main objective of the Genetic Loci and the Burden of Atherosclerotic Lesions
study is to assemble comprehensive biological networks of atherosclerosis using advanced
cardiovascular imaging for phenotyping, a panomic approach to identify underlying
genomic, proteomic, metabolomic, and lipidomic underpinnings, analyzed by systems
biologyedriven bioinformatics.
Methods: By design, this is a hypothesis-free unbiased discovery study collecting a large
number of biologically related factors to examine biological associations between genomic,
proteomic, metabolomic, lipidomic, and phenotypic factors of atherosclerosis. The Genetic
Loci and the Burden of Atherosclerotic Lesions study (NCT01738828) is a prospective,
multicenter, international observational study of atherosclerotic coronary artery disease.
Approximately 7500 patients are enrolled and undergo nonecontrast-enhanced coronaryoup, LLC.
s, Bradley Brown, and Idean Marvasty are shareholders in Global Genomics Group, LLC and
LLC. The other authors declare no conflicts of interest.
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Proteomics
Metabolomics
Lipidomicscalcium scanning by CT for the detection and quantification of coronary artery calcium, as
well as coronary artery CT angiography for the detection and quantification of plaque,
stenosis, and overall coronary artery disease burden. In addition, patients undergo whole
genome sequencing, DNA methylation, whole bloodebased transcriptome sequencing,
unbiased proteomics based on mass spectrometry, as well as metabolomics and lipidomics
on a mass spectrometry platform. The study is analyzed in 3 subsequent phases, and each
phase consists of a discovery cohort and an independent validation cohort. For the primary
analysis, the primary phenotype will be the presence of any atherosclerotic plaque, as
detected by cardiac CT. Additional phenotypic analyses will include per patient maximal
luminal stenosis defined as 50% and 70% diameter stenosis. Single-omic and multi-omic
associations will be examined for each phenotype; putative biomarkers will be assessed
for association, calibration, discrimination, and reclassification.
ª 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Background and rationale number of biologically related factors to examine biologicalFig. 1 e The DNA to RNA to protein to phenotype paradigm.
The human genome contains approximately 25,000 genes
encoded in DNA; these genes are transcribed into
approximately 100,000 RNA transcripts in different tissues
under environmental influences, regulated bymicro-RNA’s
and epigenomic regulators. The 100,000 transcripts are
translated into approximately 1,000,000 peptides andEven in the postgenomic era, primary and secondary pre-
vention of cardiovascular disease remains a significant med-
ical and societal challenge. Although inheritance contributes
up to 50% of cardiovascular disease and its intermediate
phenotypes, currently known genomic associations explain
<10% of such intermediate phenotypes,1 and as of mid-2013,
only 46 genomic loci have reached genome-wide significance
in coronary artery disease (CAD)-related genome-wide asso-
ciation studies (GWAS).2
We suggest that a comprehensive integrated solution is
required to assemble a more complete biological network that
explains atherosclerotic CAD (Fig. 1), and this solution is based
on 3 fundamental pillars: (1) next-generation phenotyping or
advanced imaging of atherosclerotic plaque, the root cause of
CAD; (2) next-generation best-in-class “panomics”; and (3)
systems biologyedriven comprehensive bioinformatics. Next-
generation phenotyping can be achieved with advanced car-
diovascular imaging, such as cardiovascular CT, because this
modality can assess atherosclerotic plaque and coronary
arterial stenosis noninvasively in a large population and has
been validated extensively. Next-generation best-in-class
panomics includes whole genome sequencing (WGS), whole
genome epigenomics, whole bloodebased full transcriptome
sequencing, as well as unbiased proteomics, metabolomics,
lipidomics, and lipoprotein proteomics (Fig. 2). As the third
pillar, the resulting high-dimensional data generated by such
an approach require a very rigorous and disciplined system-
level bioinformatics approach to maximize true discoveries
against a background of multiple testing.
Accordingly, we designed and completed enrollment in the
“Genetic Loci and the Burden of Atherosclerotic Lesions”
(GLOBAL) clinical study (NCT01738828). This manuscript de-
scribes the background, rationale, and design of the study.
proteins in the human proteome, which in turn serve as
structural components of human tissues and regulate
approximately 7000 metabolites in the human
metabolome and several hundred lipids and lipoproteins
in the human lipidome. The interaction of metabolites,
lipids, and lipoproteins in a susceptible arterial wall leads
to the development of the phenotype of vascular
atherosclerosis.2. Hypothesis
By design, this is a hypothesis-free unbiased discovery study.
Rather than testing prespecified hypotheses based on a priori
biological knowledge, we designed this study to collect a largeassociations and causality between genomic, proteomic,
metabolomic, lipidomic, and phenotypic features.3. Study design and methods
3.1. Overall study design
The GLOBAL study (NCT01738828) is a prospective, multi-
center, observational, population-based study, performed in
subjects with self-reported Caucasian ethnic background. The
Fig. 2 e Precision phenotyping and panomics. Cardiac CT shows a control subject with no atherosclerosis (A) and a subject
with severe atherosclerosis with occlusion of the right coronary artery (B). Image intensity bands from whole genome
sequencing runs are shown in (C) and (D), depicting different genetic background between cases and controls. Differential
gene expression is shown in the control subjects (E) and cases (F) based on whole bloodebased transcriptome sequencing.
Unbiased proteomics using mass spectrometry reveals differential protein expression between controls (G) and cases (H).
Different metabolic pathways are illustrated in controls (I) and cases (J).
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boards and/or ethics committees, and all patients provided
written, informed consent to specifically include the use of
genetic and/or genomic materials for research purposes.
Subjects referred for cardiac CT were enrolled; enrollment
criteria are listed in Table 1. Of note, subjects with diabetes,
those who smoke, or those on lipid-modifying therapies were
not excluded from the study.
The general study design is shown in Figure 3. The study
enrolled a total of approximately 7500 patients prospectively.
There are 3 prespecified phases of the analysis as indicated in
Figure 3 and each phase consists of 2 independent discovery
and validation cohorts. All enrolled patients have been allo-
cated to 1 of the 6 cohorts a priori. Each of the 6 analysis co-
horts contains cases and controls in an approximately 1:1
ratio. At the highest level, caseswere defined as those subjects
with any evidence of atherosclerotic plaque based on cardiac
CT; only those subjects without any evidence of atheroscle-
rotic plaque on cardiac CT were classified as controls. Of the
total of approximately 7500 patients, 500 were part of a spe-
cific cohort of patients with previous revascularization
(percutaneous coronary intervention or coronary arterybypass grafting), to represent a phenotype extreme, whereas
subjects with prior revascularization were excluded from the
main cohort. For most analyses, we perform the following
case-control comparisons for the 2 populations of cases: (1)
native CAD vs controls and (2) all CAD vs controls, where “all
CAD” includes subjects with previous revascularization.
Enrolled subjects underwent a peripheral blood draw, and
blood was aliqouted and stored as whole blood, plasma,
serum, and buffy coat. RNAwas collected in RNA preservation
tubes. Subjects undergo WGS, whole genome DNA methyl-
ation, whole bloodebased full transcriptome sequencing,
as well as mass spectrometryebased unbiased, unlabeled
proteomics, metabolomics, lipidomics, and lipoprotein
proteomics.
3.2. Cardiac CT
Cardiac CT image acquisition is performed at each partici-
pating clinical site, based on the sites’ institutional protocols
for cardiac CT (Table 2), with general image acquisition
guidelines provided to the sites by the study. Noncontrast
coronary calcium scans are analyzed for the amount of
Table 1 e Enrollment criteria.
Inclusion criteria
1. Age 18e90 years
2. White and of non-Hispanic or non-Latino origin
3. Referral for or undergoing coronary CT angiography to evaluate for the presence of CAD
4. The patient has signed the appropriate institutional review board/ethics committeeeapproved informed consent form
Exclusion criteria
1. Immunosuppressive or immunomodulatory therapy including any dose of systemic corticosteroids in the preceding 30 days
(except if steroids are administered as premedication before contrast administration for CT scan within 24 hours)
2. Chemotherapy in the preceding year
3. Major surgery in the preceding 2 months
4. Blood or blood product transfusion in the preceding 2 months
5. Subjects for whom coronary CT angiography is contraindicated per institutional standard of care
6. Subjects with previous coronary arterial revascularization (percutaneous coronary intervention or coronary artery bypass grafting)*
7. Subjects with atrial fibrillation/flutter or frequent irregular or rapid heart rhythms, which occurred within the past 3 months
8. Subjects with a pacemaker or implantable cardioverter-defibrillator implant
9. Active congestive heart failure or the presence of known nonischemic cardiomyopathy
10. Known genetic disorders of atherosclerosis, lipid, or lipoprotein metabolism
CAD, coronary artery disease.
* In the main GLOBAL cohort, previous revascularization was an exclusion criterion. However, we added an additional cohort of approximately
500 patients with previous revascularization to enrich the population in a “phenotype extreme.”
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the volume score on a per-patient and per-vessel basis.
Contrast-enhanced CT data sets are analyzed on a qualitative
and quantitative basis. For qualitative analysis, coronary
arterial segmentation is performed based on a modified
18-segment model, as suggested by the Society for Cardio-
vascular Computed Tomography3; each segment is graded for
plaque type, the degree of stenosis, plaque features, and pla-
que pattern (Fig. 4). Plaque is classified as noncalcified
plaque (NCP), partially calcified plaque, or calcified plaque.
Plaque features are assessed as proposed by Motoyama et al,4
based on the presence of positive remodeling, low-
attenuation plaque, or both. Plaque pattern is assessed asFig. 3 e Overall study design of the GLOBAL study. The
GLOBAL study is enrolling a total of approximately 7500
patients referred for cardiac CT examination. The analysis
is composed of the following 3 phases: pilot phase, interim
phase, and the entire phase; each phase has an
independent discovery cohort and an independent
validation cohort. Therefore, there are overall 6 analysis
cohorts, and each of the enrolled patients had been a priori
allocated to 1 of the 6 analysis cohorts. Each of the 6
analysis cohorts has been balanced for age, gender, and
case-control status.suggested by Maurovich-Horvat; noncalcified components of
NCP and partially calcified plaque are graded as homogenous,
heterogeneous, or having a napkin-ring sign.5 Stenosis is
graded as none, minimal (<25%), mild (25%e49%), moderate
(50%e69%), severe (70%e99%), or occluded (100%), based on
visual estimation of percent diameter stenosis (Fig. 5). Addi-
tional composite scores are also calculated as described in
Figure 6.
Quantitative CT analysis is performed as previously
described,6,7 based on a 13-segment coronary model using
Vitrea Sure Plaque (Vital Images; Minnetonka, MN; Fig. 7). For
each segment, a semiautomated method is used to calculate
geometrical parameters such as minimal luminal diameter,
minimal luminal area, percent diameter stenosis, and percent
area stenosis based on a proximal and distal reference
segment, as well as percent atheroma volume and plaque
burden. Based on attenuation values, we also quantify volume
and percent of calcified plaque, high- and low-density NCP, as
previously published (Fig. 7).73.3. End points
By design, this is a hypothesis-free unbiased discovery
experiment, and therefore, there are no prespecified end
points of the study. Primary case-control analyses are per-
formed based on the presence or absence of any atheroscle-
rotic plaque as detected by cardiac CT. Additional case-control
analyses are performed based on the maximal degree of ste-
nosis per patient using 50% and 70% diameter stenosis as a cut
point for case-control classification.3.4. Biostatistics and bioinformatics
3.4.1. Sample size calculations
Sample size calculations for the study were predicated on
principles of GWAS for a single ethnic group, reflecting the
fact that the sequence data will involve the largest number of
statistical tests, based on a discovery and a validation cohort.
Table 2 e General image acquisition guidelines for coronary calcium scans and coronary artery CT angiography (CTA).
Parameter Coronary calcium scan CTA
Scanner platform 64 slice or higher 64 slice or higher
Scan mode Volumetric, axial, or helical, as appropriate for
scanner platform and the patient’s heart rate
Volumetric, axial, or helical, as appropriate for
scanner platform and the patient’s heart rate
Electrocardiogram synchronization Prospective triggering Prospective triggering (preferred) or retrospective
gating, as appropriate for scanner platform and
the patient’s heart rate
Acquisition slice thickness 3 mm (except for Toshiba’s Aquilion ONE, where
slice thickness is 0.5 mm)
The thinnest acquisition slice thickness that is
available on the scanner platform
Scan length From the carina to just below the diaphragm to
cover the entire heart
From the carina to just below the diaphragm to
cover the entire heart
Tube current The lowest possible tube current setting to
achieve adequate image quality (image noise of
approximately 20e22 HU in small and medium
and 24 HU in large patients)
The lowest available tube current that is possible
for patient size to achieve sufficient image quality
Tube potential 120 kV The lowest available tube voltage (120 kV, 100 kV,
or 80 kV) that will give sufficient image quality
based on patient size
Contrast injection protocol Nonapplicable Optimized to achieve adequate opacification of
the left-sided cardiac chambers, the aorta, and
coronary arteries with contrast media washed
out of the right-sided cardiac chambers. Optimal
attenuation in the blood pool in the aortic root is
approximately 350e550 HU. On most scanner
systems, this will require the injection of
approximately 70e140 mL of iodinated contrast
media.
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wide significance (alpha ¼ 5  10e8); type I error for valida-
tion assumed 100 associations followed up at the significance
level alpha ¼ 5  10e4.
Under equal allocation of cases to controls, an overall
sample size of 6756 (4590 for discovery and 2166 for validation)
would provide 80% power to detect a variant of frequency
10%, exerting an effect of size 1.5 or a variant of frequency
5%, exerting an effect of size 1.8. It was noted in sample
size calculations for planned experiments of RNA expression,
proteomics, and lipidomics that fewer than 700 patients are
required to detect a fold change of 1.3 at the 5% significance
level, after adjusting for the expected number of tests.8
3.4.1.1. Single-platform analyses. Each data point will be
tested individually for association with atherosclerotic CAD,
and estimated fold changes will be reported; box plots will
allow a visual comparison of results from cases vs controls. It
is noted that some apparently missing data values simply fall
below the level of quantitation. Where appropriate, a chi-
square test will be applied to test for differences in detection
rates between cases and controls.
To allow the consideration of all features jointly, multi-
variate data-mining analyses will also be conducted using
methods such as crossvalidated gradient boosting. The latter
will allow the identification of a within-platform signature for
which the prediction performance may be assessed using the
validation set. Statistical analyses will be conducted using R,version 2.15.2 or later (R Core Team, 2012), and the Bio-
conductor Suite (Bioconductor; an open source solution).
3.4.1.2. Multiplatform analyses. It is anticipated that
the single-platform analyses will lead to biological and
mechanistic hypotheses that will be investigated in a direct
hypothesis-driven way.
In addition, the genetic basis of preliminary genomic
findings will be assessed using expression quantitative trait
locus analyses.9 Particular interest will lie in associations
which are cis-acting, that is, those which map within the vi-
cinity of the differentially expressed gene.10 Similar analyses
will be conducted for proteins, metabolites, and lipids11,12. In
this way, mechanistic hypotheses will be generated for
further investigation using, for example, epigenetic data.
Furthermore, we will be performing some novel multi-omic
integration approaches as well, such as Reverse Engineering
and Forward Simulation to test both association and causality.4. Discussion
The purpose of the present study is to further the under-
standing of more complete biological networks related to
human coronary atherosclerosis by using 3 fundamental pil-
lars: (1) advanced coronary arterial imaging by cardiac CT for
“next-generation phenotyping,” (2) panomics, and (3) systems
biologyebased bioinformatics. To our knowledge, to date, this
Fig. 4 e Plaque analysis by coronary CT angiography. Noncontrast CT is used to assess the (A) absence or (B) presence of
coronary artery calcium (arrow). Based on coronary CTA, plaque type is classified as (C) noncalcified plaque (arrow), (D)
partially calcified plaque (arrow), or (E) calcified plaque (arrow). Plaque features are classified as positive remodeling (arrow in
panel F shows external remodeling of calcified plaque), (G) low-attenuation plaque (arrow points to area of plaque with low
attenuation), and (H) positive remodelingD low-attenuation plaque (arrowspoint to enhancing rimwith positive remodeling,
surrounding a dark region of low-attenuation). Plaque pattern refers to noncalcified regions of plaques and is classified as
homogenous (arrows in part I), heterogeneous (arrow pointing to high-attenuation and arrowhead to low-attenuation area of
plaque in part J), or napkin-ring sign noncalcified plaque with enhancing ring surrounding a low-attenuation core in part K).
Calcification type is classified as (L) spotty (calcified lesions<3 mm) or (M) large (calcified lesions>3 mm).
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largest prospective studies of WGS, and the largest study of
panomics in cardiovascular disease.Fig. 5 e Qualitative segmental assessment of stenosis by CT ang
without any plaque or stenosis. (B) Minimal luminal stenosis in
distal to the first diagonal branch due to calcified plaque (arrow
calcified plaque (arrow). (D) Moderate stenosis due to partial cal
distal left main, extending into the proximal LAD. This is a par
components causing the severe stenosis at the distal left main
coronary artery; the occluded segment is characterized by very l
artery (arrows); the distal portion fills via collaterals.Phenotyping remains the cornerstone of genomic and
other “omics”-based discovery studies.13 We previously
developed and validated CT angiography (CTA)-based imageiography. (A) Normal coronary segment by CT angiography
the mid left anterior descending coronary artery (LAD) just
). (C) Mild luminal stenosis in the proximal LAD due to
cification in the mid-LAD (arrow). (E) Severe stenosis at the
tially calcified plaque, with almost exclusively noncalcified
or ostial LAD junction (arrow). (F) Occluded proximal right
ow-attenuation along the proximal and mid right coronary
Fig. 6 e Calculation of composite scores on CT angiogram. Segmentation of the right coronary artery (A), left main coronary
arteryand left anteriordescendingartery (B), and the left circumflexartery (C). See text for segmentation rules.The table shows
each segment with its associated plaque type and its score (noncalcified plaque: 1, partially calcified plaque: 2, and calcified
plaque: 3) and stenosis (none: 0,minimal: 1,mild: 2,moderate: 3, severe: 4, and occluded: 5). In this patient, SIS[ 8, SISi[ 7.5,
SSS[ 11, SSSi[ 10.4, CCS[ 24, and CCSi[ 22.6. See text for details. CAP, calcified arterial plaque; CCS, composite coronary
score; CCSi, composite coronary score index; D1, first diagonal branch; D2, second diagonal branch; dLAD, distal left anterior
descending coronary artery; dRCA, distal right coronary artery; m/dLCx, mid/distal left circumflex coronary artery; LM, left
main coronary artery;mLAD,midleft anterior descending coronary artery;mRCA,mid right coronary artery;NCP, noncalcified
plaque; OM1, first obtuse marginal branch; OM2, second obtuse marginal branch; PCP, partially calcified plaque; pLAD,
proximal left descending coronary artery; pLCx, proximal left circumflex coronary artery; pRCA, proximal right coronary
artery; RPDA, right posterior descending artery; RPLB, right posterolateral branch; SIS, segment involvement score; SISi,
segment involvement score index; SSS, segment stenosis score; SSSi, segment stenosis score index.
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image analysis protocols, the reproducibility of this technique
is excellent6,14. In addition, we have also validated thisCTA technique against intravascular ultrasonography with
radiofrequency backscatter analysis,7,15 near-infrared spec-
troscopy,6 and fractional flow reserve.15 In these studies, we
Fig. 7 e Quantitative plaque and stenosis analysis. (A)
Schematic representation of quantitative measurements
demonstrating a vessel segment, where a region of
interest is segmented. Green represents the blood-filled
lumen, light blue is lumen boundary, and orange is vessel
boundary. Yellow represents calcium, dark blue represents
high-density noncalcified plaque, and red represents low-
density noncalcified plaque. Cross-sectional views are
shown at the proximal reference (P), the site of maximal
stenosis in the lesion (L), and at the distal reference (D). (B)
Grayscale view of the vessel segment of interest
demonstrates 2 different areas of partially calcified plaque.
(C) Segmented image demonstrating the lumen in green
and plaque components in yellow (calcified plaque), high-
density noncalcified plaque (dark blue), and low-density
noncalcified plaque (red). L1 designates Lesion 1 used in
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plaque is >90%.6,16 In the intravascular ultrasound (IVUS)
studies, we showed that CTAwas able to quantify noncalcified
and calcified plaque and that low-density NCP on CTA corre-
sponds to fibro-fatty tissue and necrotic core on IVUS-virtual
histology (VH).7 In addition, we demonstrated that low-
density NCP on CT corresponds to cholesterol deposition in
the coronary arterial wall as detected by near-infrared
spectroscopy.6
In addition to morphologic validation as described previ-
ously, we have previously applied CTA as a phenotyping tool
to assess the DNA to RNA to protein to metabolite continuum.
In a candidate gene study with a trio design, we used non-
contrast CT as a phenotyping tool and showed that the M235T
polymorphism in the angiotensinogen gene is associated with
coronary arterial calcification independent of blood pres-
sure.17 In the COMPASS study, we used coronary CTA and
validated a previously developed whole bloodebased gene
expression score using quantitative measurements of 23
genes from peripheral blood measured by quantitative poly-
merase chain reaction.18,19 Furthermore, in the ATLANTA I
and II studies, we used CTA and IVUS-VH as phenotyping tools
to identify lipoproteins that were associated with specific
plaque phenotypes.20 Taken together, these studies demon-
strate that coronary CTA has been adequately validated as an
excellent phenotyping tool and can now be applied to large,
prospective, population-based studies of atherosclerosis.
The second fundamental pillar of the GLOBAL study is the
application of best-in-class next-generation panomics by
performing WGS, peripheral blood-derived whole tran-
scriptome sequencing, coupled with unbiased proteomics,
metabolomics, lipidomics, and lipoprotein proteomics. We
suggest that one of the major challenges of previous “omics”-
based discoveries has been the fact that each “omics” has
been performed in isolation; we propose that combining all
relevant omics in a single prospective cohort of precisely
phenotyped patients lays the foundation of creating more
detailed and extensive, and even novel, biological networks of
human atherosclerosis.
We estimate that the GLOBAL study will generate approxi-
mately 22 trillion data points. The detailed description of the
bioinformatics approach is beyond the scope of this manu-
script, but the high-level principles are briefly described here
(Fig. 8). We are using a carefully designed systems bio-
logyedrivenbioinformaticsapproach to synthesize thedataon
several levels. First, we will evaluate each “omics” in isolation
and will determine differential “omics” signatures between
cases and controls. Second, we will use multi-omic network
approaches to synthesize data across all omics layers to
generate comprehensive, detailed, and novel biological net-
works of atherosclerotic disease and identify “hubs,” or cen-
trally located molecules that are key regulators of these
processes. Putative biomarkers that are identified via these
methods will be prospectively validated and association,the image analysis software. Cross-sectional views at the
proximal reference (D), site of maximal stenosis (E), and
distal reference (F); color scheme as described previously.
Fig. 8 e High-level bioinformatics approach in the GLOBAL
study. It is expected that each subject will have
approximately 3 to 4 million unique DNA variants based
on whole genome sequencing. This set of DNA variants in
each subject is associated with a set of genes, proteins,
metabolites, lipids, and lipoproteins that are upregulated
and with another set of genes, proteins, metabolites,
lipids, and lipoproteins that are downregulated. This
unique constellation of biomarkers is then associated with
a specific quantitative phenotype based on cardiac CT.
SNP, single nucleotide polymorphism; SNV, single
nucleotide variant.
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lished for each biomarker and biomarker panel, as suggested
by the American Heart Association.21 In addition to biomarker
discovery, these novel biological networks of atherosclerosis
may also serve as potential opportunity for drug target dis-
covery for the treatment of atherosclerotic disease.
There are several, significant, and unique aspects to the
GLOBAL study. To our knowledge, this is the single largest
prospective study of cardiac CT study to date. Also, it is one of
the largest prospective WGS studies to date, as well as the
largest panomic study of cardiovascular disease, in a very
carefully phenotyped cohort. It is important to point out from
a design perspective that given the separate a priori defined
discovery and validation cohorts, each potential biomarker
and biomarker panel can be prospectively crossvalidated in an
independent cohort using the same phenotyping approach.5. Limitations
Although this is a prospective, multicenter, international
panomic study of atherosclerotic CAD, it has some limita-
tions. First, we are only enrolling Caucasian subjects into the
study. The reason is that based on typical GWAS sample size
calculations, approximately 7000 subjects are needed per each
ethnic group. The size, logistics, and cost associated with a
study like this in 7000 patients is already challenging enough.
However, in the future, we plan to validate any new discovery
in other ethnics groups as well. Another limitation of thepresent study design is that as described here, it is a cross-
sectional study. Although a cross-sectional study will yield
diagnostic biomarkers, a longitudinal design would be needed
to generate prognostic biomarkers. We are currently in the
process of addressing this limitation by potentially extending
the study to include a longitudinal component.6. Summary
In summary, even in the postgenomic era, the fundamental
constructs of biological networks underlying atherosclerotic
CAD are not well understood. We propose that combining
best-in-class next-generation panomics that include WGS,
peripheral bloodebased whole transcriptome sequencing,
proteomics, metabolomics, lipidomics, and lipoprotein pro-
teomics combined with advanced cardiovascular imaging for
precision phenotyping in a large prospective study will yield
novel insights into the biology of atherosclerosis, opening the
door for novel biomarker and pharmaceutical target discov-
ery. The prospective, international, multicenter GLOBAL study
is currently underway and is enrolling 7500 patients to
generate 22 trillion data points as described previously and
has the potential to contribute to the fundamental under-
standing atherosclerotic CAD and may have the potential to
bring diagnostic biomarkers and pharmaceutical solutions to
patients.Supplementary data
Supplementary data related to this article can be found online
at http://dx.doi.org/10.1016/j.jcct.2014.08.006.r e f e r e n c e s
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